DCGO Should I Buy
-
$
0.000
0.000(0.000%)
At close0.000(0.000%)Aft-market
ET
DocGo Inc (DCGO) is not a good buy for a beginner, long-term investor with $50,000-$100,000 available for investment. The stock shows weak technical indicators, poor financial performance, and lacks strong positive catalysts. Analysts have lowered price targets, and there are no significant trading trends or influential figure activity to support a bullish case.
The technical indicators for DCGO are bearish. The MACD is negative and expanding downward, the RSI is neutral at 31.532, and the moving averages are bearish (SMA_200 > SMA_20 > SMA_5). The stock is trading near its support level of 0.599, with resistance levels at 0.713 and 0.828. These indicators suggest a weak price trend with no clear reversal signals.
NULL identified. There are no recent news events, no significant insider or hedge fund trading activity, and no recent congress trading data. The company's transportation segment shows some potential for future EBITDA growth, but this is speculative.
The company reported a significant YoY revenue drop (-37.98%) and a large net income loss (-$134M). Analysts have lowered price targets, citing challenges in scaling the Mobile Health business and achieving profitability. Technical indicators are bearish, and the stock lacks momentum.
In Q4 2025, revenue dropped by 37.98% YoY to $74.94M. Net income increased to -$134.07M, reflecting a significant loss. EPS also increased to -1.37, indicating poor profitability. Gross margin decreased to 27.25%, down 11.44% YoY. Overall, the financial performance is weak, with no clear signs of recovery.
Analysts have a mixed view. Canaccord lowered the price target to $1 from $1.50 and maintains a Hold rating, citing challenges in scaling operations and achieving profitability. Stifel lowered the price target to $2.50 from $4 but maintains a Buy rating, noting potential in the transportation segment. Overall, the sentiment is cautious, with limited optimism.
